Docetaxel Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Table of Contents
1  RESEARCH SCOPE
    1.1 Research Product Definition
    1.2 Research Segmentation
        1.2.1 Product Type
        1.2.2 Main product Type of Major Players
    1.3 Demand Overview
    1.4 Research Methodology
2 GLOBAL DOCETAXEL INDUSTRY
    2.1 Summary about Docetaxel Industry
    2.2 Docetaxel Market Trends
        2.2.1 Docetaxel Production & Consumption Trends
        2.2.2 Docetaxel Demand Structure Trends
    2.3 Docetaxel Cost & Price
3  MARKET DYNAMICS
    3.1 Manufacturing & Purchasing Behavior in 2020
    3.2 Market Development under the Impact of COVID-19
        3.2.1 Drivers
        3.2.2 Restraints
        3.2.3 Opportunity
        3.2.4 Risk
4  GLOBAL MARKET SEGMENTATION
    4.1 Region Segmentation (2017 to 2021f)
        4.1.1 North America (U.S., Canada and Mexico)
        4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
        4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
        4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
        4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
    4.2 Product Type Segmentation (2017 to 2021f)
        4.2.1 40 mg/ml
        4.2.2 20 mg/ml
        4.2.3 10 mg/ml
    4.3 Consumption Segmentation (2017 to 2021f)
        4.3.1 Breast cancer
        4.3.2 Non-small cell lung cancer
        4.3.3 Prostate cancer
        4.3.4 Gastric adenocarcinoma cancer
        4.3.5 Head and neck cancer
5  NORTH AMERICA MARKET SEGMENT
    5.1 Region Segmentation (2017 to 2021f)
        5.1.1 U.S.
        5.1.2 Canada
        5.1.3 Mexico
    5.2 Product Type Segmentation (2017 to 2021f)
        5.2.1 40 mg/ml
        5.2.2 20 mg/ml
        5.2.3 10 mg/ml
    5.3 Consumption Segmentation (2017 to 2021f)
        5.3.1 Breast cancer
        5.3.2 Non-small cell lung cancer
        5.3.3 Prostate cancer
        5.3.4 Gastric adenocarcinoma cancer
        5.3.5 Head and neck cancer
    5.4 Impact of COVID-19 in North America
6  EUROPE MARKET SEGMENTATION
    6.1 Region Segmentation (2017 to 2021f)
        6.1.1 Germany
        6.1.2 UK
        6.1.3 France
        6.1.4 Italy
        6.1.5 Rest of Europe
    6.2 Product Type Segmentation (2017 to 2021f)
        6.2.1 40 mg/ml
        6.2.2 20 mg/ml
        6.2.3 10 mg/ml
    6.3 Consumption Segmentation (2017 to 2021f)
        6.3.1 Breast cancer
        6.3.2 Non-small cell lung cancer
        6.3.3 Prostate cancer
        6.3.4 Gastric adenocarcinoma cancer
        6.3.5 Head and neck cancer
    6.4  Impact of COVID-19 in Europe
7  ASIA-PACIFIC MARKET SEGMENTATION
    7.1 Region Segmentation (2017 to 2021f)
        7.1.1 China
        7.1.2 India
        7.1.3 Japan
        7.1.4 South Korea
        7.1.5 Southeast Asia
        7.1.6 Australia
        7.1.7 Rest of Asia Pacific
    7.2 Product Type Segmentation (2017 to 2021f)
        7.2.1 40 mg/ml
        7.2.2 20 mg/ml
        7.2.3 10 mg/ml
    7.3 Consumption Segmentation (2017 to 2021f)
        7.3.1 Breast cancer
        7.3.2 Non-small cell lung cancer
        7.3.3 Prostate cancer
        7.3.4 Gastric adenocarcinoma cancer
        7.3.5 Head and neck cancer
    7.4  Impact of COVID-19 in Europe
8  SOUTH AMERICA MARKET SEGMENTATION
    8.1 Region Segmentation (2017 to 2021f)
        8.1.1 Brazil
        8.1.2 Argentina
        8.1.3 Rest of Latin America
    8.2 Product Type Segmentation (2017 to 2021f)
        8.2.1 40 mg/ml
        8.2.2 20 mg/ml
        8.2.3 10 mg/ml
    8.3 Consumption Segmentation (2017 to 2021f)
        8.3.1 Breast cancer
        8.3.2 Non-small cell lung cancer
        8.3.3 Prostate cancer
        8.3.4 Gastric adenocarcinoma cancer
        8.3.5 Head and neck cancer
    8.4  Impact of COVID-19 in Europe
9  MIDDLE EAST AND AFRICA MARKET SEGMENTATION
    9.1 Region Segmentation (2017 to 2021f)
        9.1.1 GCC
        9.1.2 North Africa
        9.1.3 South Africa
        9.1.4 Rest of Middle East and Africa
    9.2 Product Type Segmentation (2017 to 2021f)
        9.2.1 40 mg/ml
        9.2.2 20 mg/ml
        9.2.3 10 mg/ml
    9.3 Consumption Segmentation (2017 to 2021f)
        9.3.1 Breast cancer
        9.3.2 Non-small cell lung cancer
        9.3.3 Prostate cancer
        9.3.4 Gastric adenocarcinoma cancer
        9.3.5 Head and neck cancer
    9.4  Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
    10.1 Brief Introduction of Major Players
        10.1.1 Sanofi-Aventis
        10.1.2 Pfizer
        10.1.3 Teva
        10.1.4 Taj Pharmaceuticals
        10.1.5 Dr. Reddy
        10.1.6 Sandoz
        10.1.7 Actavis
        10.1.8 Sun pharma
        10.1.9 Beijing Union Pharmaceutical
        10.1.10 Cisen Pharmaceutical
        10.1.11 Qilu Pharma
        10.1.12 Taiji Group
        10.1.13 Jiangsu Hengrui
        10.1.14 Accord Healthcare
        10.1.15 Eagle Pharmaceuticals
    10.2  Docetaxel Sales Date of Major Players (2017-2020e)
        10.2.1 Sanofi-Aventis
        10.2.2 Pfizer
        10.2.3 Teva
        10.2.4 Taj Pharmaceuticals
        10.2.5 Dr. Reddy
        10.2.6 Sandoz
        10.2.7 Actavis
        10.2.8 Sun pharma
        10.2.9 Beijing Union Pharmaceutical
        10.2.10 Cisen Pharmaceutical
        10.2.11 Qilu Pharma
        10.2.12 Taiji Group
        10.2.13 Jiangsu Hengrui
        10.2.14 Accord Healthcare
        10.2.15 Eagle Pharmaceuticals
    10.3  Market Distribution of Major Players
    10.4 Global Competition Segmentation
11  MARKET FORECAST
    11.1  Forecast by Region
    11.2  Forecast by Demand
    11.3  Environment Forecast
        11.3.1  Impact of COVID-19
        11.3.2  Geopolitics Overview
        11.3.3  Economic Overview of Major Countries
12  REPORT SUMMARY STATEMENT